- Home
- YQ vs CVM Comparison
YQ vs CVM Comparison
Compare YQ & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | CVM |
|---|---|---|
| Founded | 2012 | 1983 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 53.1M |
| IPO Year | 2020 | 1987 |
Fundamental Metrics
Financial Performance| Metric | YQ | CVM |
|---|---|---|
| Price | $4.78 | $6.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.7K | ★ 61.2K |
| Earning Date | 12-09-2025 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,003,071.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $1.98 |
| 52 Week High | $6.45 | $32.70 |
Technical Indicators
Market Signals| Indicator | YQ | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 43.19 |
| Support Level | $4.50 | $5.56 |
| Resistance Level | $5.23 | $6.69 |
| Average True Range (ATR) | 0.32 | 0.56 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 13.33 | 40.85 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.